Pipeline
CellantraTech is advancing two STEAP1 CAR co-lead programs through complementary in vivo and ex vivo routes, supported by targeted nonviral LNP technologies.
GUCY2C CAR and KRAS G12D TCR programs are ongoing preclinical expansion programs designed to extend the platform into additional solid-tumor targets.
DEVELOPMENT APPROACH
A Common Validation Framework Guides Program Decisions
Programs advance through a consistent evidence framework so that scientific and development decisions remain comparable across modalities.
Access
Evaluate target recognition, specificity and accessibility in the intended disease setting.
Delivery & Expression
Evaluate target-dependent uptake or expression, payload integrity, and delivery in the intended cell population.
Function & Safety
Demonstrate targeted cellular uptake, payload integrity and productive CAR or TCR expression.
Independent Confirmation
Confirm key findings through reproducible studies and appropriate controls before advancing to the next stage..
DEVELOPMENT PATH
Evidence-Gated Progression
01.
Discovery
Establish the biological thesis, therapeutic target and product concept.
02.
Preclinical Validation
Generate evidence supporting target recognition, delivery, expression and therapeutic function.
03.
Confirmatory Development
Strengthen efficacy, safety, reproducibility and product-quality evidence before IND-enabling investment.
04.
IND-Enabling Development
Integrate nonclinical, manufacturing and regulatory studies toward a potential filing package.
05.
Filing Readiness
Assemble the evidence and product-quality package required to support a potential regulatory submission.
06.
Portfolio Expansion
Advance additional targets only after predefined feasibility and evidence criteria are met.
